Dexcel Pharma, in addition to its innovative prescription products, develops, manufactures and markets a broad range of controlled-release and difficult-to-manufacture and/or develop generic products.

Dexcel Pharma's R&D team  is involved in all stages of a generic product's development, including patent evaluation, formulation and analytical development/validation, process scale-up, bioequivalence/pharmacokinetic and clinical studies.

Dexcel Pharma's regulatory affairs team submits dossiers in the US, EU, Israel and other countries.

Dexcel Pharma's pharmacovigilance unit monitors and reports adverse events for all products worldwide.

Dexcel Pharma was first to file, obtain approval for, and launch generic Omeprazole OTC 20mg in the US.

Print

© All Rights Reserved to Dexcel Ltd.

Another site by | Graphic Design OneGroup | Developed by CodeOasis |